An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
DPH001-01
Phase 1 other active
Quick answer
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers for Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
- Phase
- Phase 1
- Modality
- other
- Status
- active